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Nasal polyposis and asthma: a mechanistic paradigm   
 
Nasal polypsis and late-onset asthma are characterized by a Th2 immune response, which, 
although mostly non-allergic, involves increased IgE levels. IgE antibodies found in these 
patients are predominantly antibodies to Staphylococcus aureus enterotoxins, but not inhalant 
allergens; their expression indicates more severe upper and lower airway disease and airway co-
morbidity. S. aureus is a frequent colonizer of nasal polyps, but also has been shown to reside 
intra-mucosally, even intracellularly, and releases secreted proteins which have been 
demonstrated in the mucosa and correlate with type-2 cytokine production. Apart from 
enterotoxins, known for their superantigen activity, other secreted proteins such as serine 
protease-like proteins (Spl’s) have been identified as allergens. The secreted proteins are able to 
bias the immune response to type-2 inflammation, which results in severe impairment of the 
epithelial barrier and innate immune functions, which consequently eases the survival of S. 
aureus. A better understanding of the role of this germ in airway disease highly warrented.   
 
Key words: Nasal polyposis, CRSwNP, asthma, Staphylococcus aureus, enterotoxins, Spl’s, 
IgE, epithelial barrier, EETs, DAMPs
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Abbreviations 
Interleukin     IL 
Staphylococcus aureus  S. aureus 
CRSwNP   chronic rhinosinusitis with nasal polyps (nasal polyposis) 
Spl    serine protease like  
SE    staphylococcal enterotoxin 
PNA-FISH   peptide nucleic acid–fluorescence in situ hybridization 
ILC2s    innate lymphocytes type-2 
TSST-1   toxin shock syndrome toxin 1  
RAG    recombination activating genes  
DCs    dendritic cells 
EETs    eosinophil extracellular traps  
RAGE    receptor for advanced glycation end products 
Tregs    T regulatory cells 
TJ, AJC   tight junction, apical junctional complex 
DAMP   Danger-associated molecular pattern
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Introduction  
The link between the upper and lower airways has long been of interest, derived from 
epidemiologic observations (1, 2), but mainly focused on allergic rhinitis and asthma. Local 
tissue factors such as the airway epithelium and microbial stimuli and infections, but also 
systemic inflammatory mechanisms have been suggested to play a role in the clinical expression 
of the united allergic airway syndrome (3, 4). Mechanistic observations on this link between the 
airways boosted the discussion further: When non-asthmatic allergic rhinitis patients were 
undergoing a segmental bronchial provocation, basophils from the peripheral blood were reduced 
in numbers, whereas they increased in the bronchi, but also in the nasal mucosa (5).  
Furthermore, serum interleukin (IL)-5 and blood eosinophils increased in allergic patients after 
challenge of any compartment of the airways (6), which locally upregulated adhesion molecules 
to attract those cells from the blood; this indicated that the bloodstream might link the different 
organs.  
The finding that progenitor cells also could use the blood stream to reach active allergic areas of 
the airways furthermore introduced the bone marrow into the equation (7). The bone marrow was 
shown to release CD34(+) progenitor cells that finally differentiate into mast cells, basophils and 
eosinophils at the organ sites of the allergic reaction (8). Circulating CD34(+) cells expressed 
receptors for TSLP and IL-33, possibly derived from innate lymphocytes type-2 (ILC2s) and 
responded to these cytokines by rapidly releasing high levels of IL-5 and IL-13. Activated 
CD34(+) cells could be detected in the sputum of allergic asthmatics, and numbers increased in 
response to specific allergen inhalation. Thus, these cells distributing over the blood stream and 
attracted by the release of local chemokines are likely to contribute to the manifestation of 
allergic inflammation in different compartments of the airways. Although not specifically 
demonstrated for other type-2 inflammatory diseases of the airways such as nasal polyposis and 
late-onset athma, the same mechanisms very likely also apply here.  
Recently, the available epidemiological observations on the so-called « asthma co-morbidity » in 
chronic rhinosinusitis (CRS) without (sNP) or with nasal polyposis (wNP) have been summarized 
(9); however, a differentiation between those two major phenotypes of CRS was insufficiently 
done. Today, asthma comorbidity in CRSwNP patients has been reported be as low as 7% (e.g. in 
parts of China) to as high as 45% and more (in Europe, the US, Australia), in parallel with the 
expression of a type-2 inflammatory inflammation within the polyp tissue (10). In Europe, there 
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is a clear association between asthma and (not further defined) CRS, as shown in the Global 
Allergy and Asthma Network of Excellence (GA2LEN) study involving 52000 subjects aged 18–
75 years. A postal questionnaire in representative samples of adults living in Europe was used to 
estimate CRS prevalence as 11.9% of the European population; furthermore, there was a strong 
association of asthma with CRS at all ages. CRS in the absence of nasal allergies was positively 
associated with late-onset asthma (11). Of great interest, we also observed this phenomenon in a 
recent europe-wide GA2LEN sinusitis cohort study (unpublished); again, nasal polyposis patients 
suffered typically from late-onset often non-allergic asthma, with either of them diagnosed first, 
whereas allergic rhinitis subjects suffered from early-onset allergic asthma. However, also early 
onset asthma and allergy can be observed in CRSwNP, but rather as an independent disease, not 
impacting on the inflammatory profile of the upper airways.   
The question therefore arises what else but inhalant allergens may drive this comorbidity of 
CRSwNP with asthma, obviously able to induce even higher amounts of mucosal IgE and an 
often severe eosinophilic “type-2” inflammation?  
 
 
Staphylococcus aureus left its signature in CRSwNP and asthma 
With the support of Gunnar Johansson, who developed a specific tool to discover IgE to several 
Staphylococcus aureus enterotoxins (SE-IgEs), we investigated a small group of clinical 
CRSwNP samples and found SE-IgEs in about half of the patients (12). The SE-IgE positive 
group had high total IgE concentrations in the tissue, a severe eosinophilic inflammatory reaction, 
and frequent asthma co-morbidity. From this first observation in airway disease to the hypothesis 
of S. aureus as initiator of severe inflammation in CRSwNP (13), a wide range of epidemiologic 
as well as mechanistic studies have been performed by us and others (14), confirming the 
potential causal role of S. aureus and its secreted proteins not only in CRSwNP, but also in 
asthma.  
 
Colonisation and intramucosal presence of the germ and its secreted proteins 
It was observed early that nasal polyps were frequently colonized by S. aureus (15), whereas this 
was not obvious for the bronchi in asthma; however, in the upper as well as the lower airways, it 
was noted that macrophages were insufficiently clearing the airways from S. aureus (16, 17). In 
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an unpublished bronchial biopsy study (P. Howarth, Southampton), we observed macrophages 
with intracellular S. aureus in healthy, but extracellular bio-film forming germs in severe asthma 
subjects. Of note, it does take only a few S. aureus germs to induce and maintain an immune 
reaction, as we will discuss later.  
S. aureus has repeatedly been found intramucosally, even intracellularly in macrophages, mast 
cells and epithelial cells in CRSwNP, but not other tissues (18-20); we recently also succeeded in 
demonstrating that secreted proteins from the immune proteom of S. aureus can be fould in 
CRSwNP tissues (21). In total, more than 600 S. aureus proteins were identified by high 
resolution mass spectrometry or multiple reaction monitoring in nasal polyp tissues directly 
collected from the patients. For 115 S. aureus proteins, IgA- and IgG specific antibody signals 
were also profiled. Strong antibody signals were predominantly found for surface or secreted 
proteins, among those were also antibodies against superantigens such as SEA, SEB, SEC, 
TSST-1, SEK and others. It is obvious that the local immune response in this chronic 
inflammatory reaction does not eliminate intra-cellular persisting S. aureus nor does it abolish S. 
aureus carriage. The antibodies will exert their biological effector functions upon binding to their 
specific bacterial antigens, which will induce proinflammatory processes such as complement 
activation; evidence for that has been provided (22). Moreover, local T cell responses 
may be triggered by superantigens and other antigens leading to cytokine release of Th1/Th17 but 
also Th2 cells, depending on the nature of the antigen and the predisposition of the host. In fact, 
the frequency of carriage is strongly increased in nasal polyp patients, as discussed before (15). It 
therefore is likely that S. aureus and the innate and adaptive immune responses directed against it 
contribute to the chronic recalcitrant inflammation of the airways. This notion is supported by the 
strong relationship between the presence of IgE-immune responses to staphylococcal proteins and 
the severity of disease in upper and also lower airway diseases. Similarly, for atopic dermatitis, S. 
aureus density on lesional vs. nonlesional skin appears to be associated with disease severity 
(23). 
 
S. aureus drives IL-5 production in polyp tissue 
In a further step to demonstrate that S. aureus residing within nasal polyp tissue in CRSwNP 
patients does impact inflammation, we have analyzed CRSwNP tissue freshly obtained during 
routine surgery, which did or did not contain cultivatable S. aureus, and studied the spontaneous 
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IL-5 production by nasal polyp tissue over 24 and 72h in tissue culture. In S. aureus-positive 
samples we interfered by killing the bacteria using antibiotics or S. aureus specific ISP 
bacteriophages, active or heat-inactivated. Finally, phage-neutralizing antibodies were used to 
demonstrate the specificity of the phage-mediated effects. We monitored the number of colony-
forming units of S. aureus and identified secreted S. aureus proteins by mass spectrometry (24). 
For the first time we demonstrated that cultivatable S. aureus may be found in type-2 inflamed 
nasal polyps; the pathogen is replicating within 24h and secretes proteins, including 
superantigens and serine protease like proteins (see later). The presence of S. aureus was 
associated with a significantly higher spontaneous release of IL-5. Killing of S. aureus by 
antibiotics or specific bacteriophages significantly reduced or abolished the IL-5 release. The 
suppressive activity of the bacteriophage on IL-5 production could be abolished by heat 
inactivation or anti-phage antibodies, demonstrating the specificity of the effect of the 
bacteriophage. These experiments undoubtly indicate a direct role of S. aureus in the regulation 
of IL-5 production in nasal polyps and suggest the involvement of bacterial proteins detected in 
the tissues.  
 
Classical superantigens and IgE formation 
The classical superantigens released from the intra-mucosal germs are known to induce a 
“cytokine storm”; however, as they are released in low quantities, they contribute to the chronic 
inflammation, but do not induce a shock as it has been described with nasal or vaginal 
tamponage. Exposing normal nasal mucosa, but specifically nasal polyp tissue, to classical 
superantigens elicits a strong cytokine production including Th1, Th17 and Th2 cytokines (25). 
Specifically IL-4 and IL-13 may contribute to the strong polyclonal IgE formation that is 
observed in nasal polyps; extra-nodal lymph follicles have been demonstrated in nasal polyp 
tissues, as well as all necessary ingredients to locally switch to IgE formation such as AID, BAFF 
and recombination activating genes RAG1 and RAG2 (26-29). Of interest, switch circle 
transcripts revealed ongoing local class switch recombination to IgE, and the expression of 
RAG1 and -2, required for receptor revision, correlated with the magnitude of inflammation and 
the presence of SE-IgE in the nasal polyp mucosa (29). It recently has been elegantly 
demonstrated that indeed superantigens can activate basophils (and mast cells) by simultaneously 
binding as antigens in the conventional manner and as superantigens to framework regions of 
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anti-SEE IgE in anti-SEE IgE-FcεRI complexes (30). SEB-IgE as well as allergen-specific IgE 
present in the polyp tissue is functional and thus contributes to the chronic activation of mast 
cells (31). The presence of SE-IgE in tissue or serum furthermore may serve as proof for the 
former contact of the patient with S. aureus enterotoxins, and may therefore be used as a marker 
of interaction with superantigens and possibly severe inflammation. As diagnostic tool, we and 
others have therefore used it in  airway diseases.  
 
SE-IgE as a diagnostic marker in tissue and serum 
With the first description of the SE-IgE CAP used in tissues of nasal polyp patients (12), a tool 
was created that allowed studies in various populations of airway disease patients in tissues and 
sera.  
 
SE-IgE in nasal polyp tissue predicts asthma 
In nasal polyp tissues from 70 European and 93 Chinese patients, 34% and 8% with comorbid 
asthma, possible biomarkers of asthma comorbidity were analyzed in nasal polyp tissues (32). A 
classification tree evaluation identified IL-5 as the main positive determinant; 83% of the 
European and 16% of the Chinese polyp tissues expressed the type-2 cytokine. SE-IgE in tissue 
was associated with significantly increased total IgE and eosinophil cationic protein 
concentrations in both populations. Expression of SE-IgE within the tissue; total tissue IgE of 
greater than 1,440 kU/L; and eosinophil cationic protein of greater than 17,109 mg/L in samples 
with a total IgE concentration of greater than 246 kU/L significantly predicted asthma (odds ratio 
5.8-13). SE-IgE was not only a marker for severe inflammation in nasal polyps, it also predicted 
asthma comorbidity in CRSwNP subjects and could serve as a link between the upper and lower 
airway diseases. These findings were in agreement with the findings of a bronchial and nasal 
biopsies study, demonstrating significantly higher concentrations of Th2 cytokines in nasal 
polyps compared to inferior turbinate and bronchial biopsies (33). At the same time, the 
inflammatory profile of nasal polyps and bronchial biopsies correlated significantly (p<0.01), 
indicating that the sinuses may control the inflammation in the entire airways. 
 
SE-IgE in asthma cohortsand asthma severity 
Page 8 of 32ERS educational publications
For Review Only-ERS
Making use of adult cohorts of 69 control subjects, 152 patients with nonsevere asthma, and 166 
patients with severe asthma (defined as inadequately controlled disease despite high-dose inhaled 
corticosteroids plus at least 2 other controller therapies, including oral steroids) were analysed for 
blood biomarkers (34). Serum SE-IgE positivity was significantly greater in patients with severe 
asthma (59.6%) than in healthy control subjects (13%, P < .001). Logistic regression analyses 
demonstrated significantly increased risks for SE-IgE positive subjects to have any asthma (OR, 
7.25; 95% CI, 2.7-19.1) or severe asthma (OR, 11.09; 95% CI, 4.1-29.6) versus SE-IgE negative 
subjects. The presence of grass pollen or house dust mite IgE antibodies was not associated with 
either risk. Oral steroid use and hospitalizations were significantly increased in patients with SE-
IgE and in nonatopic asthma subjects. SE-IgE was also associated with a lower long function 
measured as FEV1 percent predicted value. SE-IgE, but not IgE against inhalant allergens, was 
thus identified as risk factor for asthma severity in both, the allergic and the non-allergic 
populations. Again, the presence of SE-IgE in serum indicated the involvement of staphylococcal 
superantigens in the pathophysiology of severe airway disease.  
The GA2LEN survey in Europe described above (11) was used again to study a random sample 
of 2908 subjects by skin prick tests for common aeroallergens and blood total IgE and SE-IgE 
measurements (35). Prevalence of positive SE-IgE was 29% and more common in smokers (<15 
pack-year: OR 1.11, P = 0.079, ≥15 pack-year: OR 1.70, P < 0.001). SE-IgE was associated with 
asthma (OR 2.10, P = 0.001) in a concentration-dependent manner. This study for the first time 
demonstrated that SE-IgE was significantly and independently associated with asthma in the 
European population. 
Similar findings were made in Korean urban and rural populations (36) consisting of 1080 adults 
(mean age 60.2 years). Positive SE-IgE had a prevalence of 27.0% in serum, risk factors were 
identified as male sex, current smoking, advanced age (≥ 61 years), and inhalant allergen 
sensitization. Current asthma was mostly adult onset (≥ 18 years old) and showed independent 
associations with high SE-IgE levels in multivariate logistic regression tests. These findings were 
confirmed in an independent even older population of 249 patients with late-onset asthma and 98 
controls above the age of 65 years (37). Elderly asthma patients with high SE-IgE levels were 
characterized by more severe asthma, sputum eosinophilia and CRS, compared to those with 
lower SE-IgE levels. The association between serum SE-IgE concentrations and severe asthma 
was significant and independent of covariables in multivariate logistic regression analysis 
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(odds ratio 7.47, P = 0.005) in SE-IgE-high (≥ 0.35 kU/L) vs. negative (< 0.10 kU/L) patients).  
Multiple correspondence analyses also showed that high serum SE-IgE level had close 
relationships with severe asthma, CRS and sputum eosinophilia. This paper prompted an 
Editorial by K.F.Chung, Imperial College London, entitled ”Staphylococcal enterotoxin-specific 
IgE: a biomarker for a distinct phenotype of severe asthma?” which indicated the possible role of 
SE-IgE as a predictor of response to Omalizumab in non-atopic late-onset asthmatics, which 
needs further study (38). As mentioned above, SE-IgE was identified as risk factor for asthma 
severity in both, the allergic and the non-allergic populations (34), and these patients are likely of 
responding well to Omalizumab (39). 
 
S. aureus is an active immune modulator to type-2 inflammation 
S. aureus is a versatile germ frequently found colonizing patients with type-2 biased diseases 
such as atopic dermatitis and CRSwNP. Compelling evidence exists showing that S. aureus 
enterotoxins act as modifying agents in the inflammatory response in upper and lower airway 
diseases (40, 41). S. aureus actively manipulates the host immune response by releasing proteins 
that facilitate bacterial invasion, colonization, and have immunomodulatory properties (Figure 1) 
(42, 43). As S. aureus has been identified as a major cofactor in atopic disease, it is important to 
understand the interplay between S. aureus and its products with the immune response of the host 
and elucidate its role in the initiation and persistence of chronic airway disease.  
 
Spls induce type 2 immune response  
Six S. aureus protease-like proteins (A-F) (abbreviated Spls) belong to a small subfamily S1B, 
encompassing staphylococcal V8 protease, epidermolytic toxins, and Spl proteases. They share 
high sequence similarity and contain putative 35- 36-amino-acid signal peptides (44). Eighty four 
percent of S. aureus strains contain at least one Spl-protease-encoding gene (45). Stentzel et al. 
demonstrated that healthy carriers have increased levels of IgG1 and IgG4 antibodies compared 
to all Spls in the blood (46). Importantly, the levels of IgE antibodies to all Spls, except for SplC, 
were significantly higher in sera of asthmatic patients compared to controls, demonstrating a 
strong link between the immune response to Spls and atopic status. SplD induces type 2 immune 
response with typical features of asthma such as airway hyperreactivity, goblet cells hyperplasia, 
Th2 cytokine production, and IgE antibody response in mice (47). Likewise, SplF, which has 95 
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% sequence homology with SplD, induces strong type 2 biased airway inflammation (47). 
Inhalation of allergens with proteolytic capacities such as house dust mite (HDM) leads to asthma 
via initiation of the TLR4 signaling pathway (48). In contrast to HDM-induced allergic asthma, 
SplD induces airway eosinophilia and specific IgE production in a TLR4-independent manner; 
the mechanisms of Spl’s sensing are not entirely clear and need further investigation. The SplD-
induced allergic features could be antagonized by soluble ST2 intratracheal treatment, 
suppressing the IL-33 mediated activation of eosinophils, innate lymphoid cells type 2, 
production of type 2 cytokine in the local lymph nodes, and reduced airway hyperreactivity, 
thereby attenuating allergic asthma symptoms in mice (47). In addition to aggravating allergic 
airway inflammation, SplD alters epithelial airway integrity, facilitating the access of other 
allergens and pollutants to the innate immune system.  
It is important to understand the interplay between the immune proteome of S. aureus and the 
immune response of the host and elucidate its role in the initiation and persistence of chronic 
airway diseases. Apart from acting as an allergen, SplD is capable of inducing specific IgE 
production to an inert protein, thus acting as an adjuvant responsible for the broadening of 
allergic immune response (47). This observation supports epidemiological studies that the 
exposure of some S. aureus secretome proteins, including enterotoxins or Spls concurrent with 
allergen exposure, could be a common factor leading to asthma susceptibility. A similar action 
was ascribed to S. aureus enterotoxins, which were shown to break tolerance to inert proteins and 
induce type 2 biased allergic immune response in mice (48, 49). 
  
S. aureus-induced tolerogenic DCs and Tregs  
Accumulating data suggests that S. aureus could produce immunomodulatory molecules 
promoting either immune tolerance (anti-inflammatory response) or pro-inflammatory responses. 
A pro-Th2 anti-inflammatory response provides a distinct advantage for S. aureus survival, thus 
facilitating bacterial persistence and chronicity of disease. The S. aureus secretome was shown to 
promote Th2 inflammation and inhibit the modulatory function of resident Tregs in vitro, while 
S. epidermididis was able to induce competent Treg production and induction of Th1 cytokines in 
the inflammation, therefore counteracting type 2 immune response (50). S. aureus phenol-soluble 
modulin peptide toxins induce tolerogenic DCs producing IL-10 with impaired capacity to induce 
activation and proliferation of CD4(+) T cells, while increasing the numbers of Tregs (51). S. 
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aureus enterotoxin B also induced DCs maturation and promoted Th2 polarization in vitro (52). 
Along with the generation of suppressive antigen-presenting cells, S. aureus secreted proteins, 
such as S. aureus enterotoxin A possesses the ability to convert neonatal conventional T cells into 
Tregs and to support Th2 polarization (53-55). Furthermore, S. aureus-derived lipoteichoic acid 
supresses T cell cytokine production (56). 
It has been estimated that the S. aureus-specific T-cell pool may comprise up to 3.6% of T-cells 
in healthy individuals (57). S.aureus-specific T cells produce Th1, Th17, and Th2 cytokines upon 
S. aureus antigen re-stimulation, therefore affecting the course of S. aureus infection. Several S. 
aureus virulence factors such as δ-toxin, delta-hemolysin (Hld), and phenol soluble modulins 
(PSMs) PSMα1 and PSMα3 promote type 2 immune responses by inducing a dose-dependent 
activation of mast cells and exacerbating allergic disease (58-60). Mast cells in the nasal mucosa 
of CRSwNP patients were shown to contain intracellular S.aureus, therefore protecting the 
bacteria from antimicrobial actions and establishing an intracellular reservoir that contributed to 
the chronic carriage in CRSwNP (20). These findings provide new insights on the role of the 
mucosal microbime in the airways, and its interplay with mucosal immune cells, which could 
modulate the inflammatory response towards type-2 biased inflammation.  
 
Eosinophil extracellular traps (EETs) in response to S. aureus  
Eosinophils are abundantly present in Th2 biased upper airway pathologies such as asthma and 
CRSwNP. They are terminally differentiated granulocytes, playing a role in innate host defense 
against pathogens through the release of toxic granule proteins and reactive oxygen species. By 
the release of their toxic contents, they can damage both pathogenic and host cells. For this 
reason, eosinophils have long been considered as harmful cells and, unsurprisingly, their presence 
in tissue or airway secretions is positively associated with the severity of both asthma and 
CRSwNP (61, 62). Beside their well-known cytotoxic activities, it is now clear that they play a 
role in both innate and adaptive immunity via different effector mechanisms. In addition, 
eosinophils can contribute to antibacterial defense by releasing DNA in association with granule 
proteins. These so called eosinophil extracellular traps (EETs) are able to bind and kill bacteria 
(63). In vitro, eosinophils are triggered to form EETs after stimulation with IL-5, TSLP, eotaxin 
and C5a (64). Interestingly, co-culture of eosinophils with S. aureus causes a rapid generation of 
EETs in the absence of any additional stimuli. Under these in vitro conditions, EETs are able to 
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entrap S. aureus and inhibit its growth in vitro (63, 65). Moreover, the exposure of eosinophils to 
TSLP, reported as an important regulator in both CRSwNP and asthma pathogenesis, also results 
in the release of EETs in vitro. TSLP-evoked EET generation seems to be dependent on CD18 
and CD11b adhesion (65, 66).  
The presence of extracellular nucleases as a defense strategy against DNA traps in several 
pathogenic bacteria, including S. aureus, Clostridium perfringens, and S. pyogenes provides 
further evidence for the pathophysiological relevance of EETs in several pathogenic conditions. 
In addition, a streptococcal DNase has previously been implicated in disease progression (67).  
The presence of EETs has been shown in multiple eosinophilic diseases, including secretions 
from eosinophilic asthma and CRSwNP patients (68, 69). Recently EETs were shown to 
contribute to the properties of highly viscous eosinophilic mucin and impairment of its clearance 
in chronic rhinosinusitis; similar viscous mucin is also  typical for asthma (69, 70). We recently 
demonstrated presence of EETs targeting S. aureus at the epithelial layer, esp. at epithelial barrier 
defects in CRSwNP; EETs can also be found above the epithelium within nasal secretions (71). 
When eosinophils are brushed from the epithelium and exposed to S. aureus, they rigorously 
release EETs (Figure 2). In nasal polyps, we showed a positive correlation between EETs and 
periostin in the tissue, the involvement of reactive oxygen species in EET generation in situ, the 
active migration of eosinophils towards and the entrapment of S. aureus in situ within a 2 hour 
time frame (71). These findings yield new insights into the possible role of EETs, and by 
extension of eosinophils, in human airways, and link S. aureus to eosinophilic airway disease 
such as CRSwNP and co-morbid asthma. In conclusion, the formation of these EETs could be 
viewed as a double edged sword providing an important mechanism of host immunity against 
infections and simultaneously causing damage to cells and tissue. 
 
Damage associated molecular patterns and their dysregulation in the airways 
It became recently apparent that some endogenous intracellular and/or extracellular matrix 
components from the host can be released into the extracellular space, subsequently gaining pro-
inflammatory functions contrasting  their regulatory functions during normal physiology. In 
analogy to “Pathogen Associated Molecular Patterns” (PAMPs) originating frm outside, these 
host-self molecules are collectively classified as “Damage Associated Molecular Patterns” 
(DAMPs) (72). DAMPs often execute their effect via activation of one or more “Toll-like 
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receptors” (TLRs) but also via other members of the pattern recognition receptor (PRR) family 
including “scavenger receptors” (eg CD36) and/or specialized receptors such as “the receptor for 
advanced glycation end products” (RAGE) (73).  
A group of molecules possessing the characteristics of DAMPs are β-defensins. These are small 
antimicrobial peptides produced in response to microbial infection of mucosal tissues and skin 
(74); β-defensins may also modulate the functional responses of inflammatory cells. Indeed, β-
defensin 2 is reported to activate dendritic cells via binding to TLR4 (75), and β-defensin 3 
similarly can activate the professional antigen-presenting DC’s and monocytes by interacting 
with TLR1 and -2 (76). Cultured sinonasal epithelial cells show decreased expression of β-
defensin 2 compared to control subjects (77). These levels were further reduced in the presence 
of the Th2 cytokines IL-4 or IL-13 while the TLR9 ligand CpG DNA increased the levels of β-
defensin 2 after the upregulation of TLR9 expression by the Th1 cytokine IFN-γ. The low β-
defensin 2 levels in nasal polyp tissues are therefore in agreement with CRSwNP being a Th2-
skewed disease for which reduced (78) or absent (79) expression of TLR9 was reported. Reduced 
levels of β-defensin 2 and -3 would result in reduced antimicrobial activity against known 
pathogens such as S. aureus (80) which play an important role in the pathophysiology of 
CRSwNP. 
The calcium-binding proteins S100A7 (psoriasin), S100A8 (MRP8 or calgranulin A), S100A9 
(MRP14 or calgranulin B), and the latters’ heterodimeric form S100A8/A9 (calprotectin) are 
reported to have antimicrobial effects (81-83). S100 proteins also show the typical activities of 
DAMPs when released to the extracellular milieu; they activate TLR4 (84, 85) and RAGE (86). 
The inflammatory and remodeling characteristics allow increased retention of S100A8, S100A9 
and S100A8/A9 proteins in the extracellular matrix. Upon release, the S100 proteins act as a local 
danger signal inducing inflammatory mediators, predominantly via TLR-4 activation (84).  
Similar to the lungs (87), RAGE is expressed in the human upper airways under normal 
physiologic conditions, but dysregulated in chronic inflammatory conditions; in CRSwNP, both 
tissue soluble sRAGE and membrane bound mRAGE protein levels are reduced (88). Reduced 
levels of mRAGE protein are associated with an increased proteolytic cleavage of the full length 
mRAGE protein which is converted to sRAGE. An imbalance between MMP’s and their natural 
“tissue inhibitors of metalloproteinases (TIMPs)” was previously reported to occur in CRSwNP 
(89), resulting in increased proteolytic cleavage. Finally, an increased colonization rate of S. 
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aureus in the airways (90) may further contribute to the overall reduction in sRAGE, as S. aureus 
induces the release of sRAGE from the ECM (88). High levels of eosinophil cationic protein 
(ECP) will break non-ECM associated sRAGE down, further reducing the levels. As RAGE is 
involved in the differentiation of T cells towards a Th1 phenotype, and RAGE deficiency 
decreases production of Th1-cytokines while increasing the production of Th2 cytokines (91), its 
deficit will prevent the redirection of T helper cells into the Th1 type. This has been confirmed in 
ex-vivo experiments showing that treatment with recombinant sRAGE significantly increased the 
release of IL-1ß and TNF-a, but decreased the levels of IL-5 in type-2 biased tissue (84).  
 
The epithelial barrier function and its impairment in Th2 inflammation 
Epithelial cells lining the airway mucosa forms not only a physical and chemical barrier to the 
outside world but also functions as an interface between innate and adaptive immune responses to 
the abundant particles, microbes, viruses and allergens that are inhaled throughout life.   
In conjunction with submucosal glands, the secretory goblet cells produce mucus, a fluid 
containing hydrated gel-forming mucins and a range of host defense and cytoprotective 
molecules, including antimicrobial molecules, antiproteases, and antioxidants that act as a 
“chemical” barrier (92). The properties of the mucus are dictated in large part by the oligomeric 
secreted mucins MUC5AC and MUC5B, multifunctional glycoproteins that provide the structural 
framework of the mucous barrier (93). The mucus traps and inactivates inhaled agents and 
facilitates their clearance via the mucociliary escalator. It is a testament to the effectiveness of the 
chemical and physical barriers of the bronchial epithelium that most environmental challenges 
are largely overcome without the need to develop an inflammatory response. This is well 
illustrated in recent studies on the importance of Muc5b for defending the airways and for 
maintaining immune homeostasis. Muc5b deficiency caused accumulation of materials in upper 
and lower airways and led to chronic infection by multiple bacterial species, including 
Staphylococcus aureus, and to inflammation that failed to resolve normally (94). An impaired 
mucociliary clearance is reported in both CRSwNP and AR and might cause an accumulation of 
antigens contributing to inflammation (95). This impairment mostly is acquired as a result of 
inflammatory or environmental stimuli such as allergens and microbial products (95).  
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The function of the respiratory mucosa barrier is largely regulated by the apical junctional 
complex between neighboring epithelial cells. Apical junctional complexes consist of tight and 
adherens junctions and link to the cellular cytoskeleton via numerous adaptor proteins (96). 
Accumulating evidence indicates that epithelial permeability or barrier dysfunction is a hallmark 
of airway inflammation and mucosal immunity. Leaky epithelium may result in greater 
penetration of inhaled allergens, bacteria, and viruses in the subepithelial space, facilitating 
antigen uptake and activating epithelial signal transduction and innate and adaptive immune 
responses. Inflammatory cytokines are known to disrupt barrier function and AJC’s in intestinal 
epithelial cells. For example, both Th1 (IFN-γ), Th2 (IL-13) and innate immune (TNF-α) 
cytokines can disrupt the structure and function of intestinal epithelial AJC’s via distinct 
mechanisms (97) IL-4 disrupts the airway epithelial barrier by altering normal structure of 
epithelial AJs and TJs via mechanisms not involving changes in junction protein expression (98). 
CRSwNP patients have a defective epithelial barrier mainly caused by secreted pro-inflammatory 
cytokines, such as IFN-c, IL-4, and oncostatin M (99). 
Allergens such as house dust mite, pollen grains, and fungi with cysteine proteinase activity, but 
likely also staphylococcal proteins with enzymatic activity, can degrade occludin and directly 
disrupt the TJ integrity (100). Endogenous protease inhibitors cystatin A and SPINK5 have been 
shown in nasal and bronchial epithelial cells; they serve to protect the airway epithelium from 
exogenous proteases (101). Compared with controls and patients with non-eosinophilic CRS, 
patients with eosinophilic CRS showed significantly lower protein and mRNA expression of 
cystatin A and SPINK5 in the nasal epithelium. Allergen-induced production of IL-25, IL-33, and 
TSLP in normal human bronchial epithelial cells, favoring type-2 inflammation, was inhibited by 
treatment with recombinant cystatin A or SPINK5, preventing the protease activity of the 
allergens (101).  
The response of the nasal epithelium to bacteria and viruses has been described to be impaired, 
inducing an inadequate cytokine and interferon release (102) and allowing the invasion of 
pathogens into the subepithelial space. When healthy mucosa is exposed to frequent viral 
intruders such as human rhinovirus or herpes simplex virus, a rigorous response from the 
epithelium with release of IFN-c and IL-17 can be expected within 24–72 h. However, in a Th2-
biased disease such as CRSwNP, this response is largely lacking; instead, significantly more pro-
inflammatory cytokines including IL-1b and TNFa are released (102). These findings were 
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associated with a significantly higher viral invasion at 48 and 72 h in CRSwNP compared to 
healthy mucosa, indicating a functional deficit in the defense against viruses. IL-4 and IL-13, 
through inhibition of TLR-3 expression and signaling (IRF3), may impair this immune response 
to viral infection (103). IL-4 and IL-13 were induced by rhinovirus in the asthmatic airway in 
vivo and relate to exacerbation severity; this induction was entirely dependent on IL-33 release 
from epithelial cells (104). IL-4 and IL-13-induced barrier dysfunction was accompanied by 
reduced expression of membrane AJC components. This study indicates that IL-4 and IL-13 have 
disruptive effect on airway epithelial barrier function. Th2-cytokine induced epithelial barrier 
dysfunction may contribute to airway inflammation in allergic asthma.  
Also impacted by Th2 cytokines, macrophages are alternatively activated, which renders them 
inadequate to phagocytize and kill bacteria, once invaded into the mucosa (105). Bacteria are 
frequently cultured from samples of severe asthma patients suggesting a defect in bacterial 
clearance from the airway. Persistence of bacteria in the lower airway may result partly from a 
reduced phagocytic capacity of macrophages for bacteria (17). Macrophages produce a variety of 
cytokines and mediators that are vital for immune and inflammatory responses in their response 
with external agents. It has been shown that there was a reduction in phagocytosis of H. 
influenzae and S. aureus by monocyte-derived macrophages from patients with severe asthma 
(104). We found a significantly lower percentage of phagocytosis of S. aureus by CD206+ cells 
in CRSwNP as compared to control inferior turbinate tissue. The clearance of non-opsonized 
bacteria by macrophages depends on their innate immune receptors for detection, binding and 
internalization of pathogens (105). In summary, we propose that the increased presence of S. 
aureus and other germs in CRSwNP can be partly explained by inefficiency of the phagocytic 
system in the sino- mucosal tissue of these patients. In line with our study, defects in 
phagocytosis of bacteria and apoptotic cells and increased bacterial colonization have been 
described for several lower airway pathologies, including asthma, cystic fibrosis and chronic 
obstructive pulmonary disease (106).  
 
Conclusion 
In the majority of patients, inflammation in the upper and the lower airways is characterized by a 
type-2 inflammation. Presence of this type of inflammation increases the risk for co-morbidity in 
the other part of the airways. In both airways, there also is severe inflammatory disease, with the 
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expression of SE-IgE as a hallmark. There is accumulating evidence that SE-IgE antibodies can 
be used as a biomarker for severe airway disease. It is yet to clarify whether S. aureus profits 
from the type-2 inflammation and its consequences such as impairment of the epithelial barrier, 
innate and adaptive immunity and secondarily modifies a pre-existing inflammation, aggravating 
the disease, or whether it may be causal in inducing an inflammation leading to disease under 
certain circumstances. It is clear today that S. aureus can reside intramucosaly, release secreted 
proteins into the mucosa, and by this regulates Th2 cytokines. It also is clear that eosinophils in 
airway disease do have a job to do defending the airways against germs such as S. aureus by 
EETs, apparantly after other defense mechanisms failed. Type-2 inflammation, impairment of 
epithelial defense mechanisms, eosinophils and EETs, and finally S. aureus and its products unite 
the airways in disease. It remains to clarify which targets are finally optimal to treat severe 
airway disease, the restauration of the epithelial barrier and immune defense, the suppression of 
adaptive immune regulators such as IL-5, IL-4, IL-13 or IgE and eosinophils, the germ and its 
products or a combination thereof.
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Figures: 
 
Figure 1: Possible strategies of S. aureus to affect type 2-biased inflammation.  Several 
secreted components of S. aureus may affect type 2 inflammation. This includes induction of 
airway hyperreactivity, stimulation of type 2 cytokine production by airway epithelium,  Th2 
cells and innate lymphoid cells type 2 (ILC2s),  production of inmmunoglobulin E  (IgE) and 
degranulation of mast cells, induction of tolerogenic dendritic cell subtypes (DCs)  and T 
regulatory cells. S. aureus protease like proteins (Spls). 
 
Figure 2: EET formation upon S. aureus exposure. DNA stain with DAPI showing an 
eosinophil (EOS) from a CRSwNP patient responding with massive EET formation (indicated by 
dashed lines) to S. aureus (some germs indicated by *) in vitro. (Scale bar = 5 µm) 
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